Metalloproteinases in Rheumatoid Arthritis: Potential Therapeutic Targets to Improve Current Therapies
Author:
- 1 January 2017
- book chapter
- Published by Elsevier
- Vol. 148, 327-338
Abstract
No abstract availableKeywords
This publication has 55 references indexed in Scilit:
- ADAM17: a molecular switch to control inflammation and tissue regenerationTrends in Immunology, 2011
- Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptorRheumatology, 2009
- Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritisNature Reviews Rheumatology, 2009
- Identification of ADAM10 as a major TNF sheddase in ADAM17-deficient fibroblastsCytokine, 2009
- Cytoplasmic tail of MT1‐MMP regulates macrophage motility independently from its protease activityGenes to Cells, 2009
- Tetraspanins Regulate ADAM10-Mediated Cleavage of TNF-α and Epidermal Growth FactorThe Journal of Immunology, 2008
- The ADAM metalloproteinasesMolecular Aspects of Medicine, 2008
- Reappraising metalloproteinases in rheumatoid arthritis and osteoarthritis: destruction or repair?Nature Clinical Practice Rheumatology, 2008
- Evolving concepts of rheumatoid arthritisNature, 2003
- ADAM17 but Not ADAM10 Mediates Tumor Necrosis Factor-α and L-Selectin Shedding from Leukocyte MembranesAntisense and Nucleic Acid Drug Development, 2001